In the second part, we discuss the primary impact factors of resistance to PD-1 inhibitors, such as tumor immune recognition, oncogenic signal pathways, interferon (IFN), immune contexture, angiogenesis, immunometabolism, intestinal microbiota, and new immune checkpoints. The gene discussed is PDCD1; the disease is neoplasm.